Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Multicenter, Phase 2 trial of selinexor (KPT-330), bortezomib and low-dose dexamethasone plus daratumumab (SELIBORDARA) for the treatment of patients with refractory or relapsed and refractory multiple myeloma

Trial Profile

An Open-label, Multicenter, Phase 2 trial of selinexor (KPT-330), bortezomib and low-dose dexamethasone plus daratumumab (SELIBORDARA) for the treatment of patients with refractory or relapsed and refractory multiple myeloma

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Aug 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bortezomib (Primary) ; Daratumumab (Primary) ; Dexamethasone (Primary) ; Selinexor (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms GEM-SELIBORDARA
  • Most Recent Events

    • 15 Jun 2023 Updated results (n=57) assessing and safety of selinexor with D-Vd for the treatment of RRMM in a phase 2,multicenter, open label study presented at the 28th Congress of the European Haematology Association
    • 14 Dec 2021 Interim Results of Selinexor in Combination with Daratumumab-Bortezomib and Dexamethasone for the Treatment of Relapse or Refractory Multiple Myeloma, presented at the 63rd American Society of Hematology Annual Meeting and Exposition
    • 04 Nov 2021 According to a Karyopharm Therapeutics media release, initial data from the study will be presented at the upcoming American Society of Hematology (ASH) 2021 Annual Meeting and Exposition.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top